Endoxifen levels and metabolic phenotype-associated factors in Mexican Mestizo patients under tamoxifen treatment

To evaluate plasma endoxifen levels and metabolic phenotype-associated factors in Mexican Mestizo patients under tamoxifen treatment. A total of 138 breast cancer patients under tamoxifen treatment were cross-sectionally evaluated and side effects (SE) were recorded. genetic phenotypes (GP) and meta...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics 2020-08, Vol.21 (13), p.929-943
Main Authors: Jorge-Aarón, Rangel-Méndez, Rodrigo, Rubi-Castellanos, Esther, Moo-Puc Rosa
Format: Article
Language:English
Subjects:
Breast cancer
Cancer therapies
CYP2D6 protein
Cytochrome P450
Deoxyribonucleic acid
DNA
endoxifen
Genotype & phenotype
Haplotypes
Hot flash
metabolic phenotype
Metabolism
Metabolites
Mexican Mestizos
Patients
Phenotypes
Tamoxifen
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate plasma endoxifen levels and metabolic phenotype-associated factors in Mexican Mestizo patients under tamoxifen treatment. A total of 138 breast cancer patients under tamoxifen treatment were cross-sectionally evaluated and side effects (SE) were recorded. genetic phenotypes (GP) and metabolic phenotypes (MP) were assessed (metabolic poor [mPM], intermediate [mIM], normal [mNM], and ultrarapid [mUM] metabolizer). Associations were tested in uni-multivariate models for endoxifen >5.9 ng/ml and for mNM + mUM MP. The main SE was hot flashes (62%). Distribution of the  MP was 4.3% mPM; 14.5% mIM; 75.4% mNM; and 5.8% mUM. Endoxifen >5.9 ng/ml was partially associated with SE (p = 0.06); the mNM + mUM MP was associated with treatment time (p = 0.03). The endoxifen-associated factors in Mexican Mestizo patients remain inconclusive, although treatment time was associated with MP.
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs-2020-0061